Sangamo (SGMO) Therapeutics has initiated a rolling submission of a BLA to the FDA seeking accelerated approval of isaralgagene civaparvovec, or ST-920, a wholly owned investigational gene therapy for ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results